BG
NVO

Bahl & Gaynor’s Novo Nordisk NVO Stock Holding History

Bahl & Gaynor’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-14,948
Closed -$405K – 408
2016
Q1 		$405K Buy
14,948
+614
+4% +$16.4K 0.01% 331
2015
Q4 		$416K Sell
14,334
-10,320
-42% -$286K 0.01% 336
2015
Q3 		$669K Buy
24,654
+194
+0.8% +$5.49K 0.01% 276
2015
Q2 		$670K Sell
24,460
-500
-2% -$14.1K 0.01% 287
2015
Q1 		$666K Hold
24,960
– – 0.01% 273
2014
Q4 		$528K Sell
24,960
-200
-0.8% -$4.47K 0.01% 287
2014
Q3 		$599K Sell
25,160
-1,600
-6% -$36.8K 0.01% 263
2014
Q2 		$618K Hold
26,760
– – 0.01% 252
2014
Q1 		$611K Sell
26,760
-1,840
-6% -$39.2K 0.01% 250
2013
Q4 		$528K Sell
28,600
-300
-1% -$5.23K 0.01% 259
2013
Q3 		$489K Hold
28,900
– – 0.01% 249
2013
Q2 		$448K Buy
+28,900
New +$481K 0.01% 244

Other funds holding NVO

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Bahl & Gaynor's NVO Position: Q2 2016 in Review

Bahl & Gaynor sold out of Novo Nordisk (NVO) in Q2 2016, closing a stake of 14,948 shares — an estimated $405K sold.

Bahl & Gaynor first reported a position in NVO in Q2 2013 and held it in 12 quarters. The position peaked at $670K in Q2 2015. 530 funds tracked by Wall St. Rank hold NVO as of Q2 2016.

  • Bahl & Gaynor reported no remaining Novo Nordisk position as of Q2 2016 after selling out during the quarter.
  • Bahl & Gaynor sold 14,948 Novo Nordisk shares in Q2 2016, an estimated $405K.
  • Bahl & Gaynor first reported a position in Novo Nordisk in Q2 2013 and held it in 12 quarters.
  • Bahl & Gaynor's Novo Nordisk position peaked at $670K in Q2 2015.
  • 530 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2016.

Based on Bahl & Gaynor's 13F filing for Q2 2016, filed 10 Aug 2016.